Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
- PMID: 30155844
- DOI: 10.1007/s11914-018-0474-4
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
Abstract
Purpose of review: Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic bone disease reflecting a compromise in the body's osseous healing mechanisms and unique to the craniofacial region. Antiresorptive and antiangiogenic medications have been suggested to be associated with the occurrence of ONJ; yet, the pathophysiology of this disease has not been fully elucidated. This article raises the current theories underlying the pathophysiology of ONJ.
Recent findings: The proposed mechanisms highlight the unique localization of ONJ. The evidence-based mechanisms of ONJ pathogenesis include disturbed bone remodeling, inflammation or infection, altered immunity, soft tissue toxicity, and angiogenesis inhibition. The role of dental infections and the oral microbiome is central to ONJ, and systemic conditions such as rheumatoid arthritis and diabetes mellitus contribute through their impact on immune resiliency. Current experimental studies on mechanisms of ONJ are summarized. The definitive pathophysiology is as yet unclear. Recent studies are beginning to clarify the relative importance of the proposed mechanisms. A better understanding of osteoimmunology and the relationship of angiogenesis to the development of ONJ is needed along with detailed studies of the impact of drug holidays on the clinical condition of ONJ.
Keywords: Anti-angiogenesis; Bone remodeling; Immunity; Inflammation; Oral infection; Osteonecrosis of the jaw.
Similar articles
-
Antiresorptive drug-related osteonecrosis of the jaw.Dent Clin North Am. 2014 Apr;58(2):369-84. doi: 10.1016/j.cden.2013.12.006. Dent Clin North Am. 2014. PMID: 24655528 Review.
-
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9. Oral Maxillofac Surg Clin North Am. 2015. PMID: 26362367 Review.
-
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.Urol Nurs. 2016 May-Jun;36(3):111-6, 154. Urol Nurs. 2016. PMID: 27501591 Review.
-
[Osteonecrosis of the jaw].Endokrynol Pol. 2011;62 Suppl 3:4-9. Endokrynol Pol. 2011. PMID: 22161980 Review. Polish.
-
Bisphosphonate-associated osteonecrosis of the jaw: patient care considerations: overview for the orthopaedic nursing healthcare professional.Orthop Nurs. 2010 May-Jun;29(3):176-80; quiz 181-2. doi: 10.1097/NOR.0b013e3181dcd2a2. Orthop Nurs. 2010. PMID: 20505486 Review.
Cited by
-
Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis.Int J Oral Sci. 2022 Apr 27;14(1):23. doi: 10.1038/s41368-022-00171-7. Int J Oral Sci. 2022. PMID: 35477924 Free PMC article.
-
Differentially Expressed Genes Reveal the Biomarkers and Molecular Mechanism of Osteonecrosis.J Healthc Eng. 2022 Jan 7;2022:8684137. doi: 10.1155/2022/8684137. eCollection 2022. J Healthc Eng. 2022. PMID: 35035862 Free PMC article.
-
Mechanical Regulation of Oral Epithelial Barrier Function.Bioengineering (Basel). 2023 Apr 25;10(5):517. doi: 10.3390/bioengineering10050517. Bioengineering (Basel). 2023. PMID: 37237587 Free PMC article.
-
Medication-related osteonecrosis of the jaws: a series of 22 cases highlighting their histopathological features.Braz Oral Res. 2025 Jun 2;39:e058. doi: 10.1590/1807-3107bor-2025.vol39.058. eCollection 2025. Braz Oral Res. 2025. PMID: 40465944 Free PMC article.
-
The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw.Front Pharmacol. 2022 May 4;13:878556. doi: 10.3389/fphar.2022.878556. eCollection 2022. Front Pharmacol. 2022. PMID: 35600875 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials